Modality
Nanobody
MOA
DLL3 ADC
Target
MALT1
Pathway
Amyloid
TTR Amyloidosis
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
Oct 2017
→ Nov 2028
Phase 1Current
NCT03031485
1,006 pts·TTR Amyloidosis
2017-10→TBD·Active
NCT04181153
2,740 pts·TTR Amyloidosis
2018-07→2028-11·Completed
3,746 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-122.6y awayPh2 Data· TTR Amyloidosis
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Active
P1/2
Complet…
Catalysts
Ph2 Data
2028-11-12 · 2.6y away
TTR Amyloidosis
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03031485 | Phase 1/2 | TTR Amyloidosis | Active | 1006 | CfB |
| NCT04181153 | Phase 1/2 | TTR Amyloidosis | Completed | 2740 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| ION-8812 | Ionis | Phase 1 | MALT1 |